human | Q5 |
P269 | IdRef ID | 078241774 |
P213 | ISNI | 0000000140161739 |
P496 | ORCID iD | 0000-0002-4301-2074 |
P214 | VIAF cluster ID | 199914238 |
P184 | doctoral advisor | André Capron | Q517594 |
P185 | doctoral student | Wassim Chehadeh | Q39190421 |
Famara Sane | Q56380428 | ||
Rachel Desailloud | Q60393992 | ||
P735 | given name | Didier | Q17978544 |
Didier | Q17978544 | ||
P106 | occupation | researcher | Q1650915 |
P21 | sex or gender | male | Q6581097 |
Q39439105 | (-)-Epigallocatechin-3-gallate is a new inhibitor of hepatitis C virus entry |
Q36350555 | A microfluidic device for on-chip agarose microbead generation with ultralow reagent consumption |
Q104691514 | A real-time quantitative PCR targeting the viral vector for the monitoring of patients treated with axicabtagene ciloleucel |
Q26801423 | Addressing Therapeutic Options for Ebola Virus Infection in Current and Future Outbreaks |
Q39238492 | Anti-coxsackievirus B4 (CV-B4) enhancing activity of serum associated with increased viral load and pathology in mice reinfected with CV-B4. |
Q40698192 | Antibodies to VP1 of swine pasivirus in humans without evidence of transmission from a pig source. |
Q38849484 | Application of bioinformatics in probe design enables detection of enteroviruses on different taxonomic levels by advanced in situ hybridization technology |
Q64360304 | Aqueous extracts of Syzygium brazzavillense can inhibit the infection with coxsackievirus B4 in vitro |
Q40166957 | Bifidobacteria-derived lipoproteins inhibit infection with coxsackievirus B4 in vitro |
Q40531437 | Central nervous system infection following vertical transmission of Coxsackievirus B4 in mice. |
Q42269037 | Clinically severe Epstein-Barr virus encephalitis with mild cerebrospinal fluid abnormalities in an immunocompetent adolescent: a case report. |
Q49793532 | Comparison of two commercial quantitative PCR assays and correlation with the first WHO International Standard for human CMV. |
Q52685431 | Comparison of two commercial quantitative PCR assays for EBV DNA detection and their correlation with the first WHO International Standard for EBV. |
Q24601560 | Confronting potential influenza A (H5N1) pandemic with better vaccines |
Q40326290 | Correlation between the anti-virus-induced cytopathic effect activity of interferon-alpha subtypes and induction of MxA protein in vitro |
Q40893867 | Coxsackievirus B4 Can Infect Human Peripheral Blood-Derived Macrophages |
Q39138391 | Coxsackievirus B4 can infect human pancreas ductal cells and persist in ductal-like cell cultures which results in inhibition of Pdx1 expression and disturbed formation of islet-like cell aggregates. |
Q37492730 | Coxsackievirus B4 infection of human fetal thymus cells |
Q98943348 | Coxsackievirus-B4 Infection Can Induce the Expression of Human Endogenous Retrovirus W in Primary Cells |
Q91587686 | Coxsackievirus-B4 Infection of Human Primary Pancreatic Ductal Cell Cultures Results in Impairment of Differentiation into Insulin-Producing Cells |
Q38172343 | Decoding norovirus infection in Crohn's disease |
Q42248756 | Detection of hepatitis B virus infection markers in dried plasma spots among patients in Congo-Brazzaville. |
Q57187160 | Diabetes progression and alterations in gut bacterial translocation: prevention by diet supplementation with human milk in NOD mice |
Q50071646 | Diabetes: Towards a coxsackievirus B-based vaccine to combat T1DM. |
Q41391190 | Diagnosis of viral infections using myxovirus resistance protein A (MxA). |
Q90331205 | Does control of glycemia regulate immunological parameters in insulin-treated persons with type 1 diabetes? |
Q95317637 | Donor-to-recipient transmission and reactivation in a kidney transplant recipient of an inherited chromosomally integrated HHV-6A: Evidence and outcomes |
Q92376577 | Emergence of Fluoxetine-Resistant Variants during Treatment of Human Pancreatic Cell Cultures Persistently Infected with Coxsackievirus B4 |
Q89968776 | Enhancing and neutralizing anti-coxsackievirus activities in serum samples from patients prior to development of type 1 diabetes |
Q97412249 | Enteroviral Pathogenesis of Type 1 Diabetes: The Role of Natural Killer Cells |
Q36550190 | Enteroviral central nervous system infections in children of the region of monastir, Tunisia: diagnosis, laboratory findings of cerebrospinal fluid and clinical manifestations |
Q37784271 | Enteroviral pathogenesis of type 1 diabetes. |
Q38095342 | Enteroviral pathogenesis of type 1 diabetes: queries and answers |
Q40070182 | Enterovirus D68 detection in respiratory specimens: Association with severe disease |
Q27008445 | Enterovirus persistence as a mechanism in the pathogenesis of type 1 diabetes |
Q99725238 | Enteroviruses and Type 1 Diabetes Mellitus: An Overlooked Relationship in Some Regions |
Q37772438 | Enteroviruses and type 1 diabetes: towards a better understanding of the relationship. |
Q38693613 | Enteroviruses in blood of patients with type 1 diabetes detected by integrated cell culture and reverse transcription quantitative real-time PCR. |
Q40063941 | Evaluation of Contamination Risks with Coxsackievirus B4 E2 in Swiss Albino Mice Stools. |
Q92499498 | Evaluation of the reverse transcription strand invasion based amplification (RT-SIBA) RSV assay, a rapid molecular assay for the detection of respiratory syncytial virus |
Q40519596 | Exposure of Piglets to Enteroviruses Investigated by an Immunoassay Based on the EV-G1 VP4 Peptide. |
Q108832228 | Fluoxetine Can Inhibit SARS-CoV-2 In Vitro |
Q57043668 | Fluoxetine can inhibit coxsackievirus-B4 E2 in vitro and in vivo |
Q37877267 | Group B coxsackieviruses and autoimmunity: focus on Type 1 diabetes. |
Q39822069 | Hepatitis delta virus proteins repress hepatitis B virus enhancers and activate the alpha/beta interferon-inducible MxA gene. |
Q40740639 | High Efficiency of Functional Carbon Nanodots as Entry Inhibitors of Herpes Simplex Virus Type 1. |
Q42200424 | Higher levels of hepatitis C virus RNA found in blood donors co-infected with HIV as compared to HCV mono-infected donors. |
Q26801632 | How Does Thymus Infection by Coxsackievirus Contribute to the Pathogenesis of Type 1 Diabetes? |
Q37262868 | Immunoglobulin G-dependent enhancement of the infection with Coxsackievirus B4 in a murine system |
Q91841227 | Impact of coxsackievirus-B4E2 combined with a single low dose of streptozotocin on pancreas of outbred mice: investigation of viral load, pathology and inflammation |
Q36267534 | In Vivo Persistence of Human Rhinoviruses in Immunosuppressed Patients |
Q34669019 | Inactivation of an enterovirus by airborne disinfectants |
Q54541397 | Infection of primary cultures of murine splenic and thymic cells with coxsackievirus B4. |
Q54240361 | Inhibition of coxsackievirus B4 by Lactobacillus plantarum |
Q40118654 | Marker of coxsackievirus-B4 infection in saliva of patients with type 1 diabetes. |
Q34017276 | Mechanisms and results of the antibody-dependent enhancement of viral infections and role in the pathogenesis of coxsackievirus B-induced diseases |
Q40799874 | Monocytes of Patients with Type 1 Diabetes Harbour Enterovirus RNA. |
Q39141892 | Necessity to critically review the automatic results of the Xpert Flu assay |
Q35914270 | New Insights into the Understanding of Hepatitis C Virus Entry and Cell-to-Cell Transmission by Using the Ionophore Monensin A. |
Q91304858 | Paediatric enterovirus meningitis without cerebrospinal fluid pleocytosis |
Q92575062 | Pancreatic beta cells persistently infected with coxsackievirus B4 are targets of NK cell-mediated cytolytic activity |
Q37721131 | Pathogenesis of type 1 diabetes mellitus: interplay between enterovirus and host |
Q38732011 | Persistent coxsackievirus B4 infection induces microRNA dysregulation in human pancreatic cells. |
Q33418888 | Persistent infection of a carcinoma thyroid cell line with coxsackievirus B. |
Q34043114 | Persistent infection of human pancreatic cells with Coxsackievirus B4 is cured by fluoxetine. |
Q39683493 | Persistent infection of human thymic epithelial cells by coxsackievirus B4. |
Q36276241 | Persistent infection of thymic epithelial cells with coxsackievirus B4 results in decreased expression of type 2 insulin-like growth factor |
Q38153686 | Programming of neuroendocrine self in the thymus and its defect in the development of neuroendocrine autoimmunity |
Q48624680 | Prolonged viral RNA detection in the central nervous system of one-week-old Swiss albino mice following coxsackievirus B4 and echovirus 9 infection |
Q88413413 | Relapsing Pityriasis Rosea With HHV-7 Reactivation in an 11-Year-Old Girl |
Q89566024 | Repeated viral meningitis in a newborn |
Q38725613 | Resistance of Enteric Viruses on Fomites. |
Q91211257 | Routine drug resistance testing in HIV-1 proviral DNA, using an automated next- generation sequencing assay |
Q59360832 | Salivary anti-coxsackievirus-B4 neutralizing activity and pattern of immune parameters in patients with type 1 diabetes: a pilot study |
Q42244449 | Serum-dependent enhancement of coxsackievirus B4-induced production of IFNα, IL-6 and TNFα by peripheral blood mononuclear cells |
Q59353109 | Serum-derived IgG from coxsackievirus A6-infected patients can enhance the infection of peripheral blood mononuclear cells with coxsackievirus A6 |
Q40725588 | Severe Adenovirus Pneumonia Followed by Bacterial Septicaemia: Relevance of Co-Infections in Allogeneic Hematopoietic Stem Cell Transplantation |
Q37740399 | Thymic self-antigens for the design of a negative/tolerogenic self-vaccination against type 1 diabetes |
Q38902114 | Vaginal Lactobacillus gasseri CMUL57 can inhibit herpes simplex type 2 but not Coxsackievirus B4E2. |
Q34123873 | Viral protein VP4 is a target of human antibodies enhancing coxsackievirus B4- and B3-induced synthesis of alpha interferon |
Q45324856 | Virus-triggered exacerbation in allergic asthmatic children: neutrophilic airway inflammation and alteration of virus sensors characterize a subgroup of patients. |
Q37126267 | Viruses and thyroiditis: an update |
Q90937254 | miRNAs in enterovirus infection |
Q517594 | André Capron | doctoral student | P185 |
Search more.